Description
Inlybest 5 mg contains Axitinib, a potent and selective tyrosine kinase inhibitor (TKI) that targets VEGFR-1, VEGFR-2, and VEGFR-3. It is commonly used in patients with advanced kidney cancer, particularly after failure of prior systemic therapy.
🔬 Mechanism of Action
Axitinib blocks VEGF receptors involved in angiogenesis (formation of new blood vessels). As a result, it:
- Reduces tumor blood supply
- Inhibits tumor growth and spread
- Limits cancer progression
This targeted anti-angiogenic effect makes it effective in managing advanced renal cell carcinoma.
💊 Indications
Inlybest 5 mg is indicated for:
- Advanced Renal Cell Carcinoma (RCC) after failure of prior therapy
- Used as monotherapy or in combination with other agents (as prescribed)
📌 Key Features
- Strength: 5 mg
- Dosage Form: Oral tablet
- Therapeutic Class: VEGFR Tyrosine Kinase Inhibitor
- Administration: Typically taken twice daily as prescribed
- Monitoring: Blood pressure, liver function tests, and thyroid function monitoring required
⚕️ Benefits
- Targeted therapy for kidney cancer
- Helps slow disease progression
- Oral administration for convenience
- Effective in second-line and combination treatment settings
⚠️ Precautions
- May cause hypertension, diarrhea, fatigue, and decreased appetite
- Risk of bleeding and thromboembolic events
- Liver function abnormalities may occur
- Dose adjustments may be required based on tolerance
- Use strictly under oncologist supervision
Inlybest 5 mg (Axitinib Tablets) provides an effective targeted treatment option for advanced renal cell carcinoma, helping control tumor progression and improve patient outcomes when used under specialized oncology care.
